Learning Objectives

“Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12–18 Years — United States, July–December 2021”

Zambrano et al., 2022, Morbidity and Mortality Weekly Report Volume 71 Issue 2, 52-58

  1. Briefly describe multisystem inflammatory syndrome in children (MIS-C)
  2. Describe benefits of vaccination in prevention of MIS-C
Session date: 
02/01/2022 - 9:30am to 10:30am CST
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Ryan Mitacek, M.D.